Summary
Overview
This comprehensive episode features Dr. Abud Bakri, an internal medicine physician and peptide expert, providing an in-depth exploration of peptides ranging from FDA-approved GLPs (like Ozempic) to research compounds like BPC-157. The discussion covers the science, safety profiles, regulatory landscape, sourcing considerations, and practical applications of various peptides including growth hormone secretagogues, thymic peptides, and bioregulators. Dr. Bakri offers unique clinical insights while emphasizing the importance of proper medical supervision and understanding the distinction between peptides with known receptors versus those without.
Introduction to Peptides: Categories and Basic Biology
Dr. Bakri establishes a foundational framework for understanding peptides as one of the body's communication languages, alongside steroid hormones. He introduces a critical distinction between peptides with known receptors (like GLPs) that have clear clinical effects, and those without identified receptors (like BPC-157 and TB-4) that work through less understood mechanisms. This categorization helps explain why some peptides have robust FDA approval while others remain in research territory.
- Peptides are one of the body's primary communication languages, going from DNA to RNA to proteins to peptides
- Peptides can be categorized into those with known receptors (strong clinical effects like GLPs) versus no clear receptor (like BPC-157, TB-500)
- Some peptides work by modifying existing proteins or linking them together for gene transcription, like Russian peptides that are epigenetic modifiers
BPC-157: Origins, Mechanisms, and Clinical Potential
BPC-157 emerges from a fascinating historical lineage dating back to Pavlov's gastric juice experiments. Dr. Bakri explains how a Croatian research group in the 1990s isolated this 15-amino-acid peptide from a larger 40,000-dalton protein found in gastric tissues. While originally intended for gastric protection, BPC-157 gained attention for musculoskeletal healing effects in animal studies. However, the lack of human data and the fact that almost all research comes from one Croatian group creates significant limitations in our understanding.
- BPC-157 is a 15-amino-acid segment from a larger BPC protein; we don't naturally make BPC-157, only the larger parent protein
- Historical context: Pavlov sold dog gastric juices as medicine in early 1900s; Croatian group isolated BPC-157 in 1991 for gastric protection
- Animal studies show accelerated healing of tendons, ligaments, nerves, and gastric ulcers, plus anti-stress effects that prevent corticosteroid-induced healing impairment
- Phase 1 and 2 human trials on ulcerative colitis using 80mg rectal enemas showed no adverse effects, but data is limited to abstracts only
- Orally or rectally administered BPC doesn't appear to go systemic based on available data; injectable forms may have different pharmacokinetics
" People are now stacking their GLP-1 as their insulin sensitivity tool, their growth hormone or their GHRH, and their androgen modulation therapies as this trinity stack to get very fit, very healthy quickly. A lot of these transformations you see in CEOs and celebrities is using a combination of those three things. "
" All the anecdata exist, but we don't have the data. There's two possibilities. Either BPC is as amazing as we think it is, and it's unfortunate that millions of people don't have access to it, or BPC is actually either ineffective or harmful to people and millions of people are injecting it right now. Both cases are very bad endpoints. "
📚 10 more sections below
Sign up to unlock the complete summary with all insights, key points, and quotes
Get this summary + all future Huberman Lab episodes in your inbox
100% Free • Unsubscribe Anytime
Sign up now and we'll send you the complete summary of this episode, plus get notified when new Huberman Lab episodes are released—delivered straight to your inbox within minutes.